Harrow, Inc. (HROW) Operating Margin
- Operating margin · 12 months: Value -1.00%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -1.00% | Operating income / revenue. Period ending 2026-06-30. $-2.75M ÷ $275.59M × 100 ≈ -1.00% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -2.75M USD | Operating Income (Loss) |
| Revenue | 275.59M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 73.64M USD | Cost of Goods and Services Sold |
| Research and development | 29.01M USD | Research and Development Expense |
| Selling, general and administration | 175.69M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-2.75M | $275.59M | $73.64M | $29.01M | $175.69M | -1.00% |
| 2026-03-31 | $19.67M | $268.68M | $69.57M | $23.81M | $155.63M | 7.32% |
| 2025-12-31 | $30.52M | $272.30M | $67.93M | $20.94M | $152.91M | 11.21% |
| 2025-09-30 | $27.82M | $250.04M | $63.60M | $13.97M | $144.39M | 11.13% |
| 2025-06-30 | $14.40M | $227.66M | $57.91M | $12.92M | $142.18M | 6.32% |
| 2025-03-31 | $4.52M | $212.86M | $54.22M | $13.11M | $140.76M | 2.12% |
| 2024-12-31 | $8.82M | $199.61M | $49.24M | $12.23M | $129.06M | 4.42% |
| 2024-09-30 | $-8.95M | $169.14M | $46.41M | $10.81M | $120.49M | -5.29% |
| 2024-06-30 | $-8.53M | $154.15M | $44.46M | $9.96M | $107.88M | -5.53% |
| 2024-03-31 | $-7.71M | $138.68M | $41.92M | $8.07M | $96.02M | -5.56% |
| 2023-12-31 | $431.00K | $130.19M | $39.64M | $6.65M | $83.09M | 0.33% |
| 2023-09-30 | $3.53M | $114.17M | $34.50M | $4.02M | $72.12M | 3.09% |
| 2023-06-30 | $1.69M | $102.72M | $31.16M | $3.37M | $66.50M | 1.65% |
| 2023-03-31 | $1.03M | $92.58M | $27.69M | $3.13M | $60.73M | 1.11% |
| 2022-12-31 | $1.92M | $88.59M | $25.38M | $3.05M | $58.24M | 2.17% |
| 2022-09-30 | $1.94M | $88.45M | $24.30M | $6.29M | $55.68M | 2.20% |
| 2022-06-30 | $-1.68M | $84.34M | $22.52M | $11.64M | $51.61M | -1.99% |
| 2022-03-31 | $798.00K | $79.15M | $20.41M | $11.15M | $46.55M | 1.01% |
| 2021-12-31 | $1.61M | $72.48M | $18.21M | $11.08M | $41.31M | 2.23% |
| 2021-09-30 | $6.00M | $66.88M | $17.07M | $7.73M | $36.08M | 8.96% |
| 2021-06-30 | $11.31M | $62.57M | $15.82M | $2.28M | $33.16M | 18.07% |
| 2021-03-31 | $3.93M | $52.50M | $14.61M | $2.60M | $31.00M | 7.49% |
| 2020-12-31 | $385.00K | $48.87M | $14.46M | $2.41M | $31.25M | 0.79% |
| 2020-09-30 | $-1.32M | $46.88M | $14.09M | $2.25M | $31.50M | -2.82% |
| 2020-06-30 | $-7.32M | $45.24M | $14.46M | $2.02M | $31.68M | -16.18% |
| 2020-03-31 | $-4.88M | $50.69M | $16.48M | $2.08M | $32.97M | -9.62% |
| 2019-12-31 | $-4.80M | $51.16M | $16.75M | $2.08M | $33.10M | -9.39% |
| 2019-09-30 | $-7.88M | $49.95M | $17.29M | $2.09M | $34.41M | -15.79% |
| 2019-06-30 | $-4.13M | $47.93M | $17.42M | $1.88M | $32.77M | -8.63% |
| 2019-03-31 | $-3.99M | $44.80M | $16.35M | $1.14M | $31.30M | -8.91% |
| 2018-12-31 | $-5.22M | $41.37M | $16.52M | $825.00K | $29.24M | -12.61% |
| 2018-09-30 | $-5.21M | $37.33M | (m) | $481.00K | (m) | -13.95% |
| 2018-06-30 | $-7.32M | $33.07M | (m) | $311.00K | (m) | -22.14% |
| 2018-03-31 | $-9.71M | $29.54M | (m) | $340.00K | (m) | -32.88% |
| 2017-12-31 | $-12.16M | $26.77M | (m) | $413.00K | (m) | -45.43% |
| 2017-09-30 | $-13.52M | $25.23M | (m) | $925.00K | (m) | -53.59% |
| 2017-06-30 | $-15.37M | $23.61M | (m) | $878.00K | (m) | -65.10% |
| 2017-03-31 | $-16.36M | $21.66M | (m) | $853.00K | (m) | -75.53% |
| 2016-12-31 | $-15.88M | $19.94M | (m) | $739.00K | (m) | -79.64% |
| 2016-09-30 | $-17.07M | $17.65M | (m) | $171.00K | (m) | -96.70% |
| 2016-06-30 | $-15.99M | $15.47M | (m) | $248.00K | (m) | -103.31% |
| 2016-03-31 | $-15.46M | $12.53M | (m) | $197.00K | (m) | -123.34% |
| 2015-12-31 | $-14.82M | $9.72M | (m) | $332.00K | (m) | -152.55% |
| 2015-09-30 | $-12.88M | $6.76M | (m) | $369.66K | (m) | -190.41% |
| 2015-06-30 | $-11.81M | $4.52M | (m) | $346.66K | (m) | -261.14% |
| 2015-03-31 | $-10.93M | $3.22M | (m) | $357.66K | (m) | -339.27% |
| 2014-12-31 | $-10.15M | $1.66M | (m) | $236.66K | (m) | -611.16% |
| 2014-09-30 | $-9.29M | (m) | (m) | $179.98K | (m) | (m) |
| 2014-06-30 | $-8.92M | (m) | (m) | $579.36K | (m) | (m) |
| 2014-03-31 | $-8.55M | (m) | (m) | $1.22M | $7.34M | (m) |
| 2013-12-31 | $-7.69M | (m) | (m) | $1.62M | $6.08M | (m) |
| 2013-09-30 | $-7.25M | (m) | (m) | $2.32M | $4.94M | (m) |
| 2013-06-30 | $-6.41M | (m) | (m) | $2.15M | $4.26M | (m) |
| 2013-03-31 | $-5.30M | (m) | (m) | $1.61M | $3.69M | (m) |
| 2012-12-31 | $-4.18M | (m) | (m) | $1.30M | $2.98M | (m) |
| 2012-09-30 | $-3.03M | (m) | (m) | $580.24K | $2.55M | (m) |
| 2012-06-30 | $-1.85M | (m) | (m) | $276.57K | $1.67M | (m) |
| 2012-03-31 | $-877.33K | (m) | (m) | $167.30K | $810.03K | (m) |
| 2011-12-31 | $-939.23K | (m) | (m) | $111.55K | $827.67K | (m) |
| 2011-09-30 | $-1.03M | (m) | (m) | $-38.76K | $1.07M | (m) |
| 2011-06-30 | $-1.69M | (m) | (m) | $104.03K | $1.59M | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-2.50M | (m) | (m) | $194.59K | $2.31M | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |